Heart Failure and Cardiomyopathies
Science News Videos from Scientific Sessions 2022
In-depth interviews from investigators and AHA experts on the Tier 1 late-breaking clinical trials
STRONG HF
Successful Post-Discharge of Heart Failure
Alexandre Mebazaa | University de Paris, Paris, France
- ClinicalTrials ID: NCT03412201
- AHA News Release: Maximizing heart failure meds within 2 weeks reduced risk of hospital readmission, death
Science News for Scientific Sessions 2022
TRANSFORM-HF
Comparative Effectiveness of Torsemide versus Furosemide in Heart Failure: Primary Results of the TRANSFORM-HF Trial
Robert J Mentz | Duke University Hospital, Durham, North Carolina
- TRANSFORM-HF trial data summary slide (PPTX)
- ClinicalTrials ID: NCT03296813
- AHA Press Release: TRANSFORM-HF trial found no difference in effectiveness between 2 common loop diuretics
- Short Video: TRANSFORM-HF Results in under 2 minutes
Science News for Scientific Sessions 2022
CRISPR ATTR
First-in-Human in vivo CRISPR/Cas9 Editing of the TTR Gene by NTLA-2001 in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Julian D Gillmore | University College of London, London, United Kingdom
- CRISPR-ATTR trial data summary (PPTX)
- AHA Press Release: Novel gene-editing therapy shows promise for patients with transthyretin amyloid cardiomyopathy
- ClinicalTrials ID: NCT04601051
- Original article: NEJM, 2021(link opens in new window)
Science News for Scientific Sessions 2022
IRONMAN
A Randomized Trial of Intravenous Ferric Derisomaltose in Heart Failure With Reduced Ejection Fraction
Paul R Kalra | Portsmouth Hospital, University NHS Trust, Portsmouth, United Kingdom
- IRONMAN Study Data Slide (PPTX)
- Simultaneously Published in The Lancet (new window)(link opens in new window)
- ClinicalTrials ID: NCT02642562
- AHA Press Release: Intravenous iron improved long-term outcomes for people with heart failure and iron deficiency
Science News for Scientific Sessions 2022
EMPA-KIDNEY
Empagliflozin and Cardiovascular Outcomes in Patients With Chronic Kidney Disease: The EMPA-KIDNEY Trial
David Preiss | University of Oxford, Oxford, United Kingdom
Science News for Scientific Sessions 2022
Science News
Journals
Continuing Education
The CLCD Council supports AHA objectives in clinical cardiology, promotes excellent clinical care, and fosters professional development and education for clinical cardiologists. Through council-sponsored symposia, panels, and scientific conferences, members can access and interpret new developments in the field and promote clinical cardiology to professional and lay audiences.
The CVSN Council accelerates the discovery, interpretation, and application of science to enhance cardiovascular health and treat cardiovascular diseases and stroke. The council helps develop scientific statements and advisories, guide professional education activities, provide scientific expertise, conduct research, translate findings, and promote evidence-based practices in clinical settings.
American Heart Association Professional Members
Enjoy instant benefits!
- Free Online Access to AHA Scientific Journals
- Affiliate with our 16 Scientific Councils
- Discounts on Scientific Conference Registration and Online Courses
